22. Okt. 2018Univ.-Prof. Dr. Christian Marth

ESMO 2018: Rezidivrisiko bei Ovarialkarzinom um 70% reduziert

Univ.-Prof. Dr. Christian Marth, Leiter der Universitätsklinik für Frauenheilkunde, Innsbruck, kommentiert die sensationellen SOLO-1-Daten, den Hype um HIPEC und die Studie 221.

Quelle: ESMO 2018

Abstracts

Moore K et al., Olaparib maintenance therapy following first-line platinum-based chemotherapy in patients with FIGO stage III–IV ovarian cancer (OC) with a BRCA1/2 mutation (BRCAm): Phase III SOLO1 trial; ESMO 2018 LBA7 PR

Pfisterer J et al., Carboplatin/pegylated liposomal doxorubicin/bevacizumab (CD-BEV) vs. carboplatin/gemcitabine/bevacizumab (CG-BEV) in patients with recurrent ovarian cancer: A prospective randomized phase III ENGOT/GCIG-Intergroup study (AGO study group, AGO-Austria, ANZGOG, GINECO, SGCTG); ESMO 2018 933O